Comparative Pharmacology
Head-to-head clinical analysis: AMMONIA N 13 versus AXUMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIA N 13 versus AXUMIN.
AMMONIA N 13 vs AXUMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia N 13 is a radioactive diagnostic agent that is used as a tracer for positron emission tomography (PET) imaging. After intravenous injection, it distributes in the body and is taken up by cells, particularly in the myocardium and brain, via active transport and passive diffusion. Its accumulation reflects regional blood flow and metabolic activity.
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; inhibits VEGFR-1, -2, -3, and PDGFR-β, Kit, and RET.
1110-1850 MBq (30-50 mCi) intravenous bolus for PET imaging; single dose per imaging session. No repeated dosing within 24 hours.
AXUMIN (florbetaben F 18) is a diagnostic radiopharmaceutical for PET imaging of beta-amyloid plaques. The recommended dose is 300 MBq (8.1 mCi) administered as a single intravenous bolus injection over 10-15 seconds, followed by a saline flush.
None Documented
None Documented
9–12 minutes (blood) for ammonia; incorporation into glutamine may extend effective half-life for imaging purposes; rapid clearance limits toxicity.
The terminal elimination half-life is approximately 2.7 hours (range 1.5-5.0 hours) in patients with normal renal function; this supports twice-daily dosing, but may be prolonged in renal impairment.
Primary renal excretion; >95% eliminated as unchanged ammonia via glomerular filtration and tubular secretion. Minimal biliary/fecal excretion.
Renal elimination of unchanged drug accounts for approximately 60% of the administered dose; fecal excretion accounts for approximately 35% (mainly as unchanged drug); biliary excretion contributes to fecal elimination; less than 1% is excreted in urine as metabolites.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical